Royalmount Biopharma Services, a division of Pharmascience, features two business units: CDMO services and lab services. Its lab division delivers high-precision bioanalytical services for preclinical and clinical studies using advanced platforms, while its CDMO services, at an FDA-approved facility, provide end-to-end development for small and large molecules, including cytotoxic products, with exclusive partnerships enabling preclinical and clinical trials; RBS combines scientific excellence, regulatory expertise and operational agility to support biopharmaceutical partners.

Chưa có bình luận nào.
Để lại đánh giá & nhận xét